Cormorant Asset Management, LLC notifies 5.81% shareholding in TiGenix
(Thomson Reuters ONE) -
REGULATED INFORMATION
PRESS RELEASE
Cormorant Asset Management, LLC notifies 5.81% shareholding in TiGenix
Leuven (Belgium) - July 20, 2016, 7:00h CEST - TiGenix NV (Euronext Brussels:
TIG) publishes today the transparency notification pursuant to Article 14 of the
Belgian Law of May 2, 2007 regarding the publication of major holdings in
issuers whose securities are admitted to trading on a regulated market and
including various provisions.
Summary of the notification
On July 19, 2016, TiGenix NV received a transparency notification from Cormorant
Asset Management, LLC, following the acquisition of shares on March 14, 2016 by
two entities controlled by it (i.e., Cormorant Global Healthcare Master Fund, LP
and CRMA SPV, LP) after which Cormorant Asset Management, LLC has the
discretionary power to exercise 11,756,894 voting rights in TiGenix NV (5.81% of
the voting rights). As a result the 5% threshold was crossed.
Content of the notification by Cormorant Asset Management, LLC
Date of the notification: July 19, 2016.
Reason of the notification: acquisition of shares.
Person subject to the notification requirement: Cormorant Asset Management, LLC,
who is a person that notifies alone.
Date on which the threshold was crossed: March 14, 2016.
Threshold that was crossed: 5%.
Denominator: 202,304,587.
Details of the notification: following the acquisition of shares, the number of
voting rights was as follows:
* Cormorant Asset Management, LLC holds 11,756,894 voting rights in TiGenix NV
(5.81% of voting rights).
Chain of controlled undertakings through which the holdings are effectively
held: Cormorant Asset Management, LLC is not a controlled entity. Cormorant
Asset Management, LLC has received the discretionary power to exercise the
voting rights of 11,756,894 TiGenix shares from the following two entities,
which are both controlled by it: Cormorant Global Healthcare Master Fund, LP and
CRMA SPV, LP.
This press release and the above-mentioned transparency notifications can be
consulted on our website:
* press release: http://www.tigenix.com/en/pages/11/2016;
* notifications: http://www.tigenix.com/en/page/26/shareholders.
For more information:
TiGenix NV
Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta(at)tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company
focused on developing and commercializing novel therapeutics from its
proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two
products from the adipose-derived stem cell technology platform are currently in
clinical development. Cx601 is in Phase III for the treatment of complex
perianal fistulas in Crohn's disease patients. Cx611 has completed a Phase I
sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective
July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product,
AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial
infarction (AMI). In addition, the second product candidate from the cardiac
stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being
developed in a chronic cardiac indication. On July 4, 2016, we entered into a
licensing agreement with Takeda, a large pharmaceutical company active in
gastroenterology, under which Takeda acquired the exclusive right to
commercialize Cx601 for complex perianal fistulas outside the United States.
TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid
(Spain). For more information, please visit www.tigenix.com.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: TiGenix via GlobeNewswire
[HUG#2029536]
Unternehmensinformation / Kurzprofil:
Datum: 20.07.2016 - 07:03 Uhr
Sprache: Deutsch
News-ID 484200
Anzahl Zeichen: 4912
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 267 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cormorant Asset Management, LLC notifies 5.81% shareholding in TiGenix"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
